ARE logo

ARE

Alexandria Real Estate Equities Inc.

$44.84
$0.00(0.00%)
56
Overall
80
Value
41
Tech
47
Quality
How is this score calculated?
Market Cap
$7.77B
Volume
2.50M
52W Range
$41.44 - $88.24
Target Price
$58.71

Company Overview

Mkt Cap$7.77BPrice$44.84
Volume2.50MChange+0.00%
P/E Ratio24.1Open$45.30
Revenue$3.1BPrev Close$44.84
Net Income$322.9M52W Range$41.44 - $88.24
Div Yield2.88%Target$58.71
Overall56Value80
Quality47Technical41

No chart data available

About Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Sector: Real Estate
Industry: REIT - Office

Latest News

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

RBC Capital analyst Luca Issi maintained a Buy rating on Ultragenyx Pharmaceutical on April 7 and set a price target of $35.00. The company’s share...

TipRanks Auto-Generated Intelligence Newsdesk9 hours ago

National Bank Reaffirms Their Buy Rating on Aecon Group Inc. (ARE)

TipRanks Auto-Generated Intelligence Newsdesk21 hours ago

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/8/2026

Shalu Sarafa day ago

Barclays Keeps Their Buy Rating on Ares Management (ARES)

TipRanks Auto-Generated Intelligence Newsdeska day ago

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/7/2026

Shalu Saraf2 days ago
ABCD
1SymbolPriceChangeVol
2ARE$44.840%2.50M
3
4
5
6

Get Alexandria Real Estate Equities Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.